|
**Overview**: Rheumatoid Arthritis Panel**Introduction**: The Rheumatoid Arthritis Panel is a diagnostic tool designed to screen for rheumatoid arthritis using serum samples. In India, RA affects ~0.5-1 percent of adults (higher in women), causing joint destruction, disability, and reduced quality of life if untreated. High morbidity from under-testing in rural/low-SES patients with early morning stiffness or polyarthritis, limited autoantibody labs, delayed DMARDs (methotrexate) leading to irreversible deformities. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for rheumatoid factor, anti-CCP, and ESR over 1-2 days with high specificity (anti-CCP >95 percent specific), valuable for early RA diagnosis per ACR/EULAR criteria. This diagnostic falls under autoimmune screening and targets patients with joint pain/stiffness >6 weeks, addressing accurate detection to guide early DMARD therapy and prevent progression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise RA identification and reducing disability burden. Its serum-based approach ensures reliable autoantibody detection.**Other Names**: RA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Anti-CCP + RF standard since 2010 ACR criteria; in India, routine in rheumatology.**Purpose**: The test assesses 3 parameters including rheumatoid factor to guide RA screening, detect autoantibodies, inform DMARD therapy.**Test Parameters**: 1. Rheumatoid Factor, 2. Anti-CCP, 3. ESR.**Pretest Condition**: Fasting 10-12 hours recommended; patients should have joint symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on joint stiffness, swelling.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated RA including deformity, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive RF/anti-CCP + high ESR supports RA diagnosis, necessitating specialist input.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: RF isotypes, X-ray hands/feet for confirmation.**Test Limitations**: RF not specific; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, RA Studies India 2023. |
